Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Mutational Profiling Predicts Clinical Outcomes to Azacytidine and Low Dose Cytarabine Plus Fludarabine (FLUGA) in Elderly Acute Myeloid Leukemia Patients Enrolled in the Pethema Phase III Flugaza Trial

Blood (2019) 134 (Supplement_1): 3891.

https://doi.org/10.1182/blood-2019-127187

Published: 2019

Journal Articles

New Alternatives for the Evaluation of Minimal Residual Disease (MRD) Detection By Next Generation Sequencing in Multiple Myeloma

Blood (2017) 130 (Supplement 1): 1783.

https://doi.org/10.1182/blood.V130.Suppl_1.1783.1783

Published: 2017

Journal Articles

Preclinical Evidence That Trametinib Enhances the Response to Tyrosine Kinase Inhibitors in Acute Myeloid Leukemia

Joaquín Martínez-López, MD PhD, María Linares, Maria Luz Morales, Alicia Arenas, Ivana Zagorac, Rosa M. Ayala, MD PhD, Nerea Castro, Inmaculada Rapado, PhD, Miguel Quintela-Fandino

Blood (2016) 128 (22): 1581.

https://doi.org/10.1182/blood.V128.22.1581.1581

Published: 2016

Journal Articles

Ultra-Deep Targeted Sequencing Does Not Identify MM Patients with Different Prognosis: Results from a Randomized Phase II Clinical Trial

Blood (2016) 128 (22): 2078.

https://doi.org/10.1182/blood.V128.22.2078.2078

Published: 2016

Journal Articles

Safety and Efficacy of Dasatinib Treatment Change for Patients Previosly Treated with Imatinib with Late Warning Response. Results from the Phase II, Open, Multicenter Dasapost Study

Valentín García-Gutierrez, MD, Felipe Casado, Fermín Sánchez-Guijo, MD PhD, Rosa M. Ayala, MD PhD, Concepcion Boque, PhD, Blanca Xicoy, MD, Isabel Montero, MD, Cesar Soto, Raquel De Paz, PhD, Joaquin Martinez-Lopez, Juan Luis Steegmann, MD

Blood (2016) 128 (22): 5450.

https://doi.org/10.1182/blood.V128.22.5450.5450

Published: 2016

Journal Articles

Nilotinib Plus Ruxolitinib Produces Anti-Fibrotic Effect

Alicia Arenas, Rosa M. Ayala, MD PhD, María Linares, PhD, Joaquín Martínez-López, MD PhD

Blood (2016) 128 (22): 5497.

https://doi.org/10.1182/blood.V128.22.5497.5497

Published: 2016

Journal Articles

Prognostic Impact of Molecular Response Assessed By Next-Generation Sequencing in a Large Cohort of Multiple Myeloma Patients

Beatriz Sanchez-Vega, PhD, Rafael Alonso, MD, Isabel Cuenca, Santiago Barrio, PhD, Yanira Ruiz-Heredia, Carlos Marin, Inmaculada Rapado, PhD, Cristina Jimenez, BSc, Xabier Aguirre, Rosa M. Ayala, MD PhD, Teresa Cedena, Bruno Paiva, PhD, Maria-Victoria Mateos, MD PhD, Laura Rosiñol, Joan Bladé, Jesus San Miguel, MD PhD, Ramon Garcia-Sanz, MD PhD, Juan José Lahuerta, MDPhD, Joaquín Martínez-López, MD PhD

Blood (2016) 128 (22): 3283.

https://doi.org/10.1182/blood.V128.22.3283.3283

Published: 2016

Journal Articles

A Study of the Role of Antiplatelet Therapy in the Prevention of Thrombosis in Patients with Calr -Mutated Low Risk Essential Thrombocythemia

Blood (2015) 126 (23): 1602.

https://doi.org/10.1182/blood.V126.23.1602.1602

Published: 2015

Journal Articles

A Way to Individualized Therapy in Acute Myeloid Leukemia (AML): NGS Mutational Profile and Ex Vivo Pharmacological Test (Ex-viTech)

Esther Onecha, Joan Ballesteros, Jose L Rojas, Jose M Sanchez, Eva Barragan, PhD, Inmaculada Rapado, PhD, Santiago Barrio, David Martinez, MD PhD, Pau Montesinos, MD, Pilar Herrera, MD PhD, Carmen Burgaleta, MD, Joaquin Martinez-López, MDPhD, Rosa M. Ayala, MD PhD

Blood (2015) 126 (23): 1376.

https://doi.org/10.1182/blood.V126.23.1376.1376

Published: 2015

Journal Articles

Measurement of PTCH1 Expression at Diagnosis Is an Appropriate Tool for Tyrosine Kinase Inhibitors Selection in Chronic Myeloid Leukemia Patients in Chronic Phase

Juan Manuel Alonso-Dominguez, MD, Felipe Casado, MariaTeresa Gómez Casares, MDPhD, Ismael Buno, Francisca Ferrer-Marin, Eduardo Anguita, MD PhD, Alicia Arenas, Rafael Del Orbe, MD, Rosa M. Ayala, MD PhD, Pilar Llamas, MD, Pedro Sanchez-Godoy, MD, Carmen Burgaleta, MD, Valentín García-Gutierrez, Juan Luis Steegmann, MD PhD, Joaquin Martinez-Lopez

Blood (2015) 126 (23): 2791.

https://doi.org/10.1182/blood.V126.23.2791.2791

Published: 2015

Journal Articles

Efficacy and Safety of Dasatinib in Late Suboptimal Response CML Patients a Its Relation with Lymphocytosis, Lymphocyte Migration and Chemokine Receptor Expression

Valentín García-Gutierrez, Beatriz Colom-Fernandez, Anna Kreutzman, PhD, Luis Felipe Casado, Fermín Sánchez-Guijo, MD, Rosa M. Ayala, MD PhD, Concepcion Boque, PhD, Blanca Xicoy, MD PhD, Isabel Montero, MD, Cesar Soto, Raquel De Paz, Joaquin Martinez Lopez, MDPhD, Cecilia Muñoz-Calleja, Juan Luis Steegmann, MD

Blood (2015) 126 (23): 4015.

https://doi.org/10.1182/blood.V126.23.4015.4015

Published: 2015

Journal Articles

Simplified in-House Deep Sequencing Method of Inmunoglobulin Genes for Minimal Residual Dissease Quantification and Risk Stratification in Multiple Myeloma

Blood (2015) 126 (23): 2972.

https://doi.org/10.1182/blood.V126.23.2972.2972

Published: 2015

Journal Articles

Ruxolitinib in Combination with Nilotinib and Prednisolone, a New Synergistic Approach to Treat Myelofibrosis

Alicia Arenas, Pilar Hernandez-Campo, PhD, Julian Gorrochategui, Daniel Primo, PhD, Rosa M. Ayala, MD PhD, Blanca Ferrer-Lores, MD, Joan Ballesteros, PhD, Joaquin Martinez-Lopez, MD PhD

Blood (2014) 124 (21): 903.

https://doi.org/10.1182/blood.V124.21.903.903

Published: 2014

Journal Articles

Wilms’ Tumor 1 Expression Levels in Bone Marrow after Induction and/or Consolidation Therapy Allow a Better Stratification of Patients and Improves Treatment in Adult AML

Blood (2014) 124 (21): 1036.

https://doi.org/10.1182/blood.V124.21.1036.1036

Published: 2014

Journal Articles

Correlation Between Clinical Features, CRLF2 Expression and Copy Number Alterations In Acute Lymphoblastic Leukemia

Juan Carlos Ponce Jarquin, Rosa M. Ayala, MD, PhD, Ana Belen Dueñas Perez, MD, PhD, Daniel Rueda, María Luisa Martin Ramos, José Luis Vivanco, MD, PhD, Pilar Martinez Sánchez, MD, PhD, Rafael Alberto Alonso Fernandez, Florinda Gilsanz Rodriguez, Joaquin Martinez -Lopez

Blood (2013) 122 (21): 4953.

https://doi.org/10.1182/blood.V122.21.4953.4953

Published: 2013

Journal Articles

FLT3, PIM and CXCR4 Expression In Acute Myeloid Leukemia

Rafael Alonso Fernández, Inmaculada Rapado, MD, Castro Nerea, MD, Pilar Martinez-Sanchez, MD, Ascensión Peña, MD, Luis Garcia-Alonso, MD, Montserrat Rubio, MD, Antonia Rodriguez, MD, Maria del Pilar Martinez-Barranco, MD, Maria del Carmen Calle, MD, Maria Jose Otero, MD, Juan Carlos Ponce, Florinda Gilsanz-Rodriguez, Rosa M. Ayala, MD, PhD, Joaquin Martinez-Lopez, MD, PhD

Blood (2013) 122 (21): 4957.

https://doi.org/10.1182/blood.V122.21.4957.4957

Published: 2013

Journal Articles

Prognostic Value Of Deep Sequencing Approach For Minimal Residual Disease (MRD) Detection In Multiple Myeloma Patients

Blood (2013) 122 (21): 1848.

https://doi.org/10.1182/blood.V122.21.1848.1848

Published: 2013

Journal Articles

High Throughput Screening, With a Flow Cytometry Automated Platform (Ex vivo Biotech), To Identify Potential Combination Partners, For The JAK 2 Inhibitor Ruxolitinib

Alicia Arenas, Pilar Hernandez-Campo, Daniel Primo, Santiago Barrio, PhD, Rosa M. Ayala, MD, PhD, Joan Ballesteros, Joaquín Martínez-López, MD, PhD

Blood (2013) 122 (21): 2534.

https://doi.org/10.1182/blood.V122.21.2534.2534

Published: 2013

Journal Articles

Inhibition of Related JAK/STAT Pathways with Molecular Targeted Drugs Shows Strong Synergy with Ruxolitinib in Chronic Myeloproliferative Neoplasms

Santiago Barrio, Miguel Gallardo, Alicia Arenas, Rosa M. Ayala, MD, PhD, Inmaculada Rapado, Daniel Rueda, PhD, Ana Jimenez, Enriqueta Albizua, Carmen Burgaleta, Florinda Gilsanz, MD, PhD, Joaquin Martinez, MD

Blood (2012) 120 (21): 5054.

https://doi.org/10.1182/blood.V120.21.5054.5054

Published: 2012

Journal Articles

Under Scope of the Current Redefinition Process of Optimal Response in Multiple Myeloma: Assesment of Molecular Response by Fluorescent PCR of Ig Genes Has Similar Applicability and Prognosis Impact to Immunophenotypic Response. (A GEM/PETHEMA study),

Blood (2011) 118 (21): 3951.

https://doi.org/10.1182/blood.V118.21.3951.3951

Published: 2011

NARROW

Mutational Profiling Predicts Clinical Outcomes to Azacytidine and Low Dose Cytarabine Plus Fludarabine (FLUGA) in Elderly Acute Myeloid Leukemia Patients Enrolled in the Pethema Phase III Flugaza Trial

New Alternatives for the Evaluation of Minimal Residual Disease (MRD) Detection By Next Generation Sequencing in Multiple Myeloma

Preclinical Evidence That Trametinib Enhances the Response to Tyrosine Kinase Inhibitors in Acute Myeloid Leukemia

Ultra-Deep Targeted Sequencing Does Not Identify MM Patients with Different Prognosis: Results from a Randomized Phase II Clinical Trial

Safety and Efficacy of Dasatinib Treatment Change for Patients Previosly Treated with Imatinib with Late Warning Response. Results from the Phase II, Open, Multicenter Dasapost Study

Nilotinib Plus Ruxolitinib Produces Anti-Fibrotic Effect

Prognostic Impact of Molecular Response Assessed By Next-Generation Sequencing in a Large Cohort of Multiple Myeloma Patients

A Study of the Role of Antiplatelet Therapy in the Prevention of Thrombosis in Patients with Calr -Mutated Low Risk Essential Thrombocythemia

A Way to Individualized Therapy in Acute Myeloid Leukemia (AML): NGS Mutational Profile and Ex Vivo Pharmacological Test (Ex-viTech)

Measurement of PTCH1 Expression at Diagnosis Is an Appropriate Tool for Tyrosine Kinase Inhibitors Selection in Chronic Myeloid Leukemia Patients in Chronic Phase

Efficacy and Safety of Dasatinib in Late Suboptimal Response CML Patients a Its Relation with Lymphocytosis, Lymphocyte Migration and Chemokine Receptor Expression

Simplified in-House Deep Sequencing Method of Inmunoglobulin Genes for Minimal Residual Dissease Quantification and Risk Stratification in Multiple Myeloma

Ruxolitinib in Combination with Nilotinib and Prednisolone, a New Synergistic Approach to Treat Myelofibrosis

Wilms’ Tumor 1 Expression Levels in Bone Marrow after Induction and/or Consolidation Therapy Allow a Better Stratification of Patients and Improves Treatment in Adult AML

Correlation Between Clinical Features, CRLF2 Expression and Copy Number Alterations In Acute Lymphoblastic Leukemia

FLT3, PIM and CXCR4 Expression In Acute Myeloid Leukemia

Prognostic Value Of Deep Sequencing Approach For Minimal Residual Disease (MRD) Detection In Multiple Myeloma Patients

High Throughput Screening, With a Flow Cytometry Automated Platform (Ex vivo Biotech), To Identify Potential Combination Partners, For The JAK 2 Inhibitor Ruxolitinib

Inhibition of Related JAK/STAT Pathways with Molecular Targeted Drugs Shows Strong Synergy with Ruxolitinib in Chronic Myeloproliferative Neoplasms

Under Scope of the Current Redefinition Process of Optimal Response in Multiple Myeloma: Assesment of Molecular Response by Fluorescent PCR of Ig Genes Has Similar Applicability and Prognosis Impact to Immunophenotypic Response. (A GEM/PETHEMA study),

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only